Currently, majority of the ongoing clinical trials are utilizing MV-NIS construct rather than MV-CEA, possibly due to NIS having greater clinical applicability as MV-NIS could enhance the accumulation of therapeutic radioisotopes at the tumor lesions and induce additional antitumor effect in preclinical models (114). The gene discussed is SLC5A5; the disease is neoplasm.